Interesting Images68Ga-FAPI PET/CT Improves Therapeutic Strategy by Detecting a Second Primary Malignancy in a Patient With Rectal CancerChen, Haojun MD, PhD*; Zhao, Liang MD†; Ruan, Dan MD*; Sun, Long MD, PhD*; Lin, Qin MD, PhD†Author Information From the *Department of Nuclear Medicine & Minnan PET Center †Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, China. Received for publication December 27, 2019; revision accepted January 22, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Qin Lin, MD, PhD, 55 Zhenhai Road, Xiamen 361003, China. E-mail: email@example.com. Clinical Nuclear Medicine: June 2020 - Volume 45 - Issue 6 - p 468-470 doi: 10.1097/RLU.0000000000003000 Buy Metrics Abstract A 71-year-old man with pathologically confirmed rectal cancer underwent 18F-FDG PET/CT before radical operation, which showed multiple nodules with low uptake in bilateral pleura and 1 solitary pulmonary nodule with slight uptake in left lung. The subpleural nodule was diagnosed as benign lesion through the biopsy. 68Ga-labeled fibroblast-activation-protein inhibitor PET/CT was performed for further evaluation, which showed low uptake in bilateral subpleural nodules but focally increased uptake in the nodule of left lung. This nodule was found to be a primary lung adenocarcinoma by the CT-guided biopsy. A diagnosis of rectum and lung double primary malignancies was finally made. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.